To keep up to date with news from this category use our
IMS Health to Launch Oncology Quantifier, Delivering Integrated Insights for Enhanced Market Measurement, Commercial Strategies
NORWALK, CT, November 11, 2009 - IMS Health (NYSE: RX), the world's leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the upcoming launch of IMS Oncology...
Simcyp Simulator aids in preclinical ADME assessment of Genentech compound
November 11, 2009--A recent paper, by researchers at Genentech, describes the preclinical evaluation of the pharmacokinetic properties of GDC-0449, a potent selective Hedgehog signalling pathway inhibitor which is being...
Conclusion of the Agreement on Apaziquone for Non-muscle invasive bladder cancer
November 11, 2009 -- Nippon Kayaku Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, Japan; President: Koichiro Shimada) concluded the agreement on apaziquone (generic name) for non-muscle invasive bladder cancer (superficial...
The European Commission grants Orphan Drug designation for NGR-hTNF in the treatment of hepatocellular carcinoma
Milan (Italy), 11 November 2009 - MolMed S.p.A. (Milan:MLM) announces that the European Commission has granted Orphan Drug designation for MolMed's investigational new antitumour therapeutic drug NGR-hTNF in the...
YM BIOSCIENCES REPORTS FISCAL FIRST QUARTER 2010 OPERATIONAL AND FINANCIAL RESULTS
MISSISSAUGA, ON, Nov. 11, 2009- YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various...
Lonza successfully develops a manufacturing process for ArzerraTM (ofatumumab), a new biopharmaceutical from GSK and Genmab
Basel, Switzerland, 10 November 2009 - Lonza announces that GlaxoSmithKline (GSK) and Genmab's antibody ArzerraTM, which has just been approved for use in patients with chronic lymphocytic leukemia (CLL) by the US Food...
University of Cambridge and Life Technologies Collaborate on Landmark High Throughput Sequencing Hub in United Kingdom
CARLSBAD, Calif.-- November 10, 2009-- The University of Cambridge and Life Technologies Corporation (NASDAQ:LIFE), announced today the formation of a collaboration to advance translational research studies in key...
BIOVEX COMPLETES $70 MILLION FINANCING TO CONCLUDE PIVOTAL STUDY WITH ITS PIONEERING CANCER TREATMENT, ONCOVEXGM-CSF
Woburn, MA, November 10, 2009 -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a $70 million private...
FDA Approves Gloucester Pharmaceuticals' ISTODAX
Cambridge, MA - November 5, 2009 - Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved ISTODAX
FDA GRANTS ORPHAN DRUG DESIGNATION FOR TNFERADE(TM)
GAITHERSBURG, MD - November 4, 2009 - GenVec, Inc. (NASDAQ: GNVC) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to TNFerade(TM) for the treatment of pancreatic...
Thirteen Abstracts Featuring Exelixis Compounds Accepted for Presentation at the 2009 AACR-NCI-EORTC International Conference
SOUTH SAN FRANCISCO, Calif.-- November 4, 2009-- Exelixis, Inc. (Nasdaq: EXEL) announced today that thirteen abstracts related to the company's development candidates have been accepted for presentation at the 2009...
Acceleron Pharma Initiates First-in-Human Study of ACE-041, a Novel Angiogenesis Inhibitor, in Patients with Advanced Cancer
CAMBRIDGE, Mass. November 4, 2009 Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the...
Transgene: First Patient enrolled in Phase I Trial of TG4023 for the Treatment of Liver Tumours
Strasbourg, France, November, 4th, 2009 - Transgene S.A. (Euronext Paris: FR0005175080) today announced the enrolment of the first patient in the Phase I trial of TG4023 (MVA-FCU1), its newest product to enter clinical...
XOFT SHOWCASES MULTI-DISCIPLINARY ELECTRONIC BRACHYTHERAPY CANCER TREATMENT PLATFORM AT ASTRO
CHICAGO, Nov. 2, 2009 - Xoft, Inc., developer of the Axxent
BIOVEX ANNOUNCES PUBLICATION OF PHASE 2 MELANOMA RESULTS WITH ONCOVEXGM-CSF IN THE JOURNAL OF CLINICAL ONCOLOGY
Woburn, MA, November 2, 2009 -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from its completed Phase 2...
YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009
MISSISSAUGA, ON, Nov. 2 , 2009 - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at...
Cancer trials and good manufacturing practice
October 30, 2009--An article in Friday's issue of the Danish medical journal 'Dagens Medicin' accuses the Danish Medicines Agency of delaying the development of new cancer medicine. The specific case involves an...
Varian Medical Systems Selected to Supply Major Project to Bring Advanced Radiotherapy Treatments to North of Portugal Cancer Patients to Benefit from State-of-the-Art RapidArc and Novalis Tx Installations
PORTO, Portugal, Oct. 30, 2009-- Cancer patients in northern Portugal will gain access to advanced cancer treatments with the acquisition of seven new treatments machines from Varian Medical Systems (NYSE: VAR) by the...
CEL-SCI Corporation Strengthens Balance Sheet Through Receipt of $10 Million From Warrant Exercises
VIENNA, Va., Oct. 26 -- CEL-SCI Corporation (NYSE Amex: CVM) announced today that it has received over $10 million over the past 60 days through the exercise of warrants by investors to purchase the Company's common...
Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
October 26, 2009 - Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has...
Bayer and Onyx Initiate Phase III Trial of Nexavar
Berlin, October 23, 2009 - Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. today announced that the companies have begun enrolling patients in an international Phase III trial to evaluate Nexavar
Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer
SOUTH SAN FRANCISCO, Calif. & NEW YORK-- October 23, 2009-- Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today reported updated phase 2 clinical data which show that XL184 demonstrated...
PRIMA BIOMED SECURES JAPANESE PATENT FOR CANCER VAC
October 22, 2009--Australian health care company Prima BioMed (Prima) (ASX: PRR) is pleased to announce that its subsidiary company, Cancer Vac Pty Ltd, has received a Decision to Grant from the Japanese Patent Office...
Pixantrone Produces High Rates of Complete Remission in Multiple Relapsed and Refractory Indolent and Aggressive Non-Hodgkin's Lymphoma
SEATTLE, Oct. 22 -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an...
Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial with Subcutaneous Herceptin(R)
SAN DIEGO, Oct 22, 2009 -- Halozyme Therapeutics, Inc. (Nasdaq:HALO) and Roche today announced dosing of the first patient in a Phase 3 registration trial using Enhanze(TM) technology (rHuPH20, recombinant human...
Two new appointments to BioAlliance Pharma's Supervisory Board in phase with the company's development
Paris, October 21, 2009 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the appointment of two new Board members.
Endocyte presents data on EC145 in treatment of ovarian cancer at the 16th annual meeting of the European Society of Gynaecologic Oncology
WEST LAFAYETTE, Ind. -October 21, 2009 - Endocyte, Inc., a cancer drug discovery and development company, presented data from a Phase 2a clinical trial for EC145, currently in development as a potential treatment for...
Antigenics Announces a Negative Vote From the CHMP on Oncophage
London, UK -- October 21, 2009 -- Antigenics Inc. (NASDAQ: AGEN) today announced that the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMEA), has verbally informed the Company...
Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data at the IDF's 20TH World Diabetes Congress
MONTREAL, CANADA - October 21, 2009 - Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating T-cell activity,...
Alfacell Corporation Announces Closing of $3.25 Million Private Placement
SOMERSET, N.J., Oct. 20, 2009 -- Alfacell Corporation (Pink Sheets:ACEL) today announced that it has closed a private placement with certain investors in which it raised $3.25 million in gross proceeds through the sale...
Pixantrone Produces High Rates of Complete Remission in Multiple Relapsed and Refractory Indolent and Aggressive Non-Hodgkin's Lymphoma
SEATTLE, Oct. 22-- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an...
CRT to License Telomere Targeting Agents to Pharminox for Drug Development
London and Nottingham UK, 13 October 2009 - Cancer Research Technology (CRT) - Cancer Research UK's development and commercial arm - and the cancer drug discovery company Pharminox Ltd (Pharminox) today announced that...
Optimata Releases a New Version of its Virtual Patient
October 13, 2009---Optimata Ltd announces the release of a new Optimata Virtual Patient
ONCOLYS BIOPHARMA SIGN STRATEGIC ALLIANCE AND LICENSE AGREEMENT WITH ASTELLAS PHARMA TO DEVELOP AND COMMERCIALIZE YM753 HDAC INHIBITOR DRUG
Tokyo, Japan -- October 13, 2009 -- Oncolys BioPharma Inc. (headquarters: Tokyo; President and CEO: Yasuo Urata) announced today that it has entered into a strategic alliance and license agreement with Astellas Pharma...
ELECTRONIC BRACHYTHERAPY A VIABLE OPTION FOR INTRAOPERATIVE RADIATION THERAPY (IORT)
CHICAGO, Oct. 12, 2009 - Clinical experience with the FDA cleared Axxent
BioAlliance Pharma announces Phase I trial for Fentanyl Lauriad
Paris, October 12, 2009 - BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the approval from the French Drug Agency...
GENVEC RECEIVES NATIONAL CANCER INSTITUTE GRANT TO EXPAND CANCER PROGRAM
GAITHERSBURG, MD - September 30, 2009 - GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase I Small Business Innovation and Research (SBIR) grant from the National Cancer Institute (NCI) of the...
Clavis Pharma ASA receives USD 1.1 million Grant from Innovation Norway
Oslo, Norway, 27 August 2009--Clavis Pharma ASA (OSE: CLAVIS) announced today that it has received a government grant of up to USD 1.1 mill (NOK 6.9 mill) to accelerate the Phase II clinical programme with Intravenous...
Tarix Pharmaceuticals receives FDA approval for Phase 2 study to mitigate chemotherapy-induced thrombocytopenia
Brookline,MA , June 25, 2008 -- Tarix Phamaceuticals announced that it has received FDA approval to begin a Phase II clinical trial of TXA127 for the prevention of chemotherapy induced thrombocytopenia. The trial will...
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
